Lund (Sweden) – March 18, 2013, NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company announces that Anna Malm Bernsten and Boel Flodgren have been elected to the Company’s Board. Both have exceptional track records and leadership experience and are expected to make a significant contribution to NeuroVive.
Anna Malm Bernsten has more than 25 years of international marketing and sales experience in the healthcare industry. She was until recently Chief Marketing Officer at GE Healthcare Life Sciences, where she established a marketing leadership team, developing branding and communication strategies for the company’s key brands. Anna also gained global sales experience as Vice President Global Sales at Aerocrine AB and developed her leadership skills as Chief Executive Officer at Carmeda AB. Anna is currently on the board of a number of companies including Nolato AB, CellaVision AB, Medivir AB and Fagerhult AB and she was previously on the board of Biophausia AB. Anna has an MSc in Chemical Engineering from the Royal Institute of Technology, Stockholm.
Boel Flodgren is a Senior Professor of Business Law at the School of Economics and Management at Lund University. She brings to NeuroVive a wealth of academic knowledge in law and regulatory issues. She was the President of Lund University for ten years and has been awarded honorary doctorate degrees from HANKEN (The Swedish School of Economics and Business Administration), Helsinki, Finland, from McGill University, Montreal, Canada and from the University of Oslo, Norway. Her research focuses on Contract Law and International Trade Law. Boel has served on the Boards of the Universities of Lund, Copenhagen and Oslo and is currently a Director of AB Industrivärden.
Anna and Boel join Helena Levander, who was appointed in 2012, on NeuroVive’s seven person Board. Helena has over 30 years of experience in equity fund and asset management. Helena is managing partner and co-founder of Nordic Investor Services AB, where she is responsible for strategic development and marketing. Prior to this position, she was Chief Executive Officer at Neonet Securities AB, where she developed an international stock exchange trading network and prepared the Company for its listing on the Stockholm Stock Exchange in 2000. She holds a BSc in Business and Economics from Stockholm School of Economics and completed the “International Banking Programme” at INSEAD. Helena is a Director of several companies, including SBAB Bank, Uniflex Bemanning, Stampen and Collector.
Greg Batcheller, Chairman of NeuroVive Pharmaceutical said: “NeuroVive’s ability to attract such high calibre board members as Anna and Boel highlights our attractive growth potential as one of the world’s leading companies in mitochondrial medicine. I am pleased that NeuroVive is clearly in the vanguard of promoting gender equality at Board level. With these new appointments, alongside the appointment of Helena last year, women now account for 3 out of the 7 person Board of Directors. I believe that with these appointments we now have a balanced Board which has the experience, leadership and independence to support NeuroVive through its next stage of growth as we advance our attractive pipeline of novel mitochondrial medicines and as we prepare for listing on the Nasdaq OMX Stockholm Stock Exchange.”
About NeuroVive Pharmaceutical AB (publ)
NeuroVive Pharmaceutical AB (www.neurovive.com) a leading mitochondrial medicine company is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.
NeuroVive’s products are based on the cyclophilin inhibitor cyclosporine and work by preventing the death of mitochondria in distressed cells and the subsequent cascade of intracellular biochemical events that lead to secondary tissue damage following an acute cardiac or traumatic brain injury.
NeuroVive’s lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries following stenting. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction.
NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is soon expected to enter a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options. Both CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications.
NeuroVive’s pipeline includes novel cyclophilin inhibitors, and drug candidates that act on mitochondria to address energy regulation disorders.
NeuroVive´s shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.
Media and investor relations contacts
NeuroVive Pharmaceutical: Mikael Bronnegard
Phone No: +46 (0) 70 299 62 64
Citigate Dewe Rogerson: Nina Enegren / David Dible
Phone No: +44 207 282 1050